Metzger-Filho, Otto
Collier, Katharine http://orcid.org/0000-0003-0485-8031
Asad, Sarah
Ansell, Peter J.
Watson, Mark
Bae, Junu
Cherian, Mathew
O’Shaughnessy, Joyce
Untch, Michael
Rugo, Hope S.
Huober, Jens B.
Golshan, Mehra
Sikov, William M. http://orcid.org/0000-0001-5451-6449
von Minckwitz, Gunter
Rastogi, Priya
Li, Lang
Cheng, Lijun
Maag, David
Wolmark, Norman
Denkert, Carsten http://orcid.org/0000-0002-2249-0982
Symmans, W. Fraser http://orcid.org/0000-0002-1526-184X
Geyer, Charles E. Jr. http://orcid.org/0000-0002-2379-5702
Loibl, Sibylle
Stover, Daniel G. http://orcid.org/0000-0001-9003-8165
Funding for this research was provided by:
Alliance Foundation [to D.G.S.] and Breast Cancer Research Foundation [to D.G.S.]
Conquer Cancer Foundation
Article History
Received: 24 June 2021
Accepted: 11 October 2021
First Online: 11 November 2021
Competing interests
: C. Denkert reports stock and other ownership interests in Sividon Diagnostics (until 2016); honoraria from Novartis and Roche; consulting or advisory roles for MSD Oncology, Daiichi Sankyo, Molecular Health, AstraZeneca, and Merck; research funding (paid to institution) from Myriad Genetics and Roche; travel, accommodations, expenses from Roche; and patents, royalties, other intellectual property from VMScope digital pathology software (Patent applications WO2015114146A1 and WO2010076322A1- therapy response; Patent application WO2020109570A1 - cancer immunotherapy).